Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

The first was a one-time stock option exchange program for non-Executive Committee employees, which received significant support from stockholders. The second proposal allowed for the adjournment of ...

Q3 earnings beat estimates but pipeline setback and lower 2025 guidance raise concerns. Full analysis of results and outlook.

The S&P 500 Healthcare sector (XLV) experienced a slight rise in average short interest during October, moving from 1.91% to ...

The story of the pharmaceutical company Moderna almost reads like a Hollywood screenplay. In its relatively short life, it ...

In this week's STATus Report, STAT reporters Jason Mast and Damian Garde discuss the challenges facing Moderna — and what could be in store for its third act.

With the greater part of third quarter earnings results in the rearview mirror, investors are looking ahead to marquee ...

With the greater part of third quarter earnings results in the rearview mirror, investors are looking ahead to marquee ...

Merck rebounds on pipeline wins and a $9.2B Cidara deal, but mixed trends and Keytruda risks keep investors weighing next moves.

With the greater part of third quarter earnings results in the rearview mirror, investors are looking ahead to marquee ...

Roivant Sciences Ltd.'s innovative model and breakthrough autoimmune drug pipeline make it a strong buy. Click here to read ...

Analysts also weigh in on Chesapeake Utilities, Halozyme Therapeutics, Sea Ltd., and Roper Technologies. Trump reverses on tariffs for some imports, Bitcoin falls on details of strategic reserve, ...